Skip to content

Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer

Alcohol Related Cancers and Genetic Susceptibility in Europe Follow-up - North-West England

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02049177
Acronym
ARCAGE-NWE
Enrollment
141
Registered
2014-01-30
Start date
2013-11-30
Completion date
2014-04-30
Last updated
2016-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

Cancer, Epidemiology, Head and Neck, HPV

Brief summary

Human papilloma virus (HPV) is a recognised cause of some head and neck cancers. Important questions remain however, regarding the role of specific types of HPV, their effect on prognosis and different subtypes of oral, pharyngeal and laryngeal cancer, interaction with other risk factors (such as smoking and alcohol), and potential geographical differences in the effect of HPV. Via the Alcohol-Related Cancers and Genetic Susceptibility in Europe (ARCAGE) study, which is an international collaboartive case-control study conducted in 15 centres in 11 European countries, and pooling our results with the HPV-AHEAD consortium, we will conduct a systematic analysis of HPV subtypes known or suspected to be involved in head and neck cancer. This will involve investigation of HPV risk by tumour site (oral, oropharynx, hypopharynx, larynx), tumour stage, country, sex and age, and whether risk is modified by exposure to other known or suspected carcinogens including tobacco, alcohol and medical history. It is intended that this work will contribute to the development of evidence that may feed into treatment protocols for these cancers as well as evaluations of the feasibility for extending HPV vaccine programs.

Interventions

None listed

Sponsors

International Agency for Research on Cancer
CollaboratorOTHER
University of Aberdeen
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consent to follow-up and use of tissue samples

Exclusion criteria

* No existing consent

Design outcomes

Primary

MeasureTime frame
HPV typeFrom surgical/biopsy samples taken in 2002/2003, to be typed in 2014

Secondary

MeasureTime frame
Secondary cancers2002-2014
Vital status2014
Cancer Reccurrence2002-2014

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026